Filing Flows › Caris Life Sciences (CAI) › Q3 2026 › vs Q3 2025
Caris Life Sciences (CAI) Q3 2026 vs Q3 2025 (year over year)
Caris Life Sciences's revenue rose $58.5M (+27%) from $217M in Q3 2025 to $275M in Q3 2026. The biggest changes: Molecular Profiling Services +$55.1M (+27%); Pharma Research and Development Services +$3.4M (+37%). Operating margin 7.0% against 15.1% (-8.0 pts).
Caris Life Sciences, Q3 2026: revenue $275M (+27% year over year), operating margin 7.0%, net earnings $15.2M, operating cash flow −$22.2M. The chart draws each line against Q3 2025, the increases inside each band.
Margins
| Q3 2026 | Q3 2025 | Change | |
|---|---|---|---|
| Operating margin | 7.0% | 15.1% | -8.0 pts |
| Net margin | 5.5% | 11.2% | -5.7 pts |
Every line
| Line | Q3 2026 | Q3 2025 | Change | % |
|---|---|---|---|---|
| Molecular Profiling Services | $263M | $208M | $55.1M | +27% |
| Pharma Research and Development Services | $12.7M | $9.2M | $3.4M | +37% |
| Revenue | $275M | $217M | $58.5M | +27% |
| Operating profit | $19.3M | $32.6M | −$13.3M | -41% |
| Costs & expenses | $256M | $184M | $71.9M | +39% |
| Pre-tax earnings | $16.9M | $24.3M | −$7.5M | -31% |
| Other expense, net | $2.4M | $8.3M | −$5.9M | -71% |
| Research & development | $33.8M | $21.6M | $12.2M | +56% |
| Sales & marketing | $59.9M | $41.3M | $18.6M | +45% |
| General & admin | $69.3M | $52.0M | $17.3M | +33% |
| Other operating costs | $93.1M | $69.3M | $23.7M | +34% |
| Net earnings | $15.2M | $24.3M | −$9.1M | -37% |
| Income tax | $1.6M | $0 | $1.6M | — |
| Operating cash sources | $62.6M | −$19.5M | $82.1M | — |
| Depreciation & amortization | $6.6M | $4.9M | $1.7M | +35% |
| Share-based compensation | $18.5M | $13.7M | $4.8M | +35% |
| Cash used in operations | $22.2M | −$62.4M | $84.7M | — |
| Working capital & other | $62.6M | −$19.5M | $82.1M | — |
Questions
How much did Caris Life Sciences's revenue grow year over year in Q3 2026?
Caris Life Sciences's revenue rose $58.5M (+27%) from $217M in Q3 2025 to $275M in Q3 2026.
What drove Caris Life Sciences's revenue change in Q3 2026?
Molecular Profiling Services +$55.1M (+27%); Pharma Research and Development Services +$3.4M (+37%).